Rapid onset of tardive dyskinesia in huntington disease with olanzapine [3]

Journal of Clinical Psychopharmacology

Volumn 22, Issue 4, 2002, Pages 438-439

  Benazzi, Franco ^a  

^a National Health Service   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONAZEPAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DOPAMINE 2 RECEPTOR; NORCITALOPRAM; OLANZAPINE; SEROTONIN RECEPTOR;

ADULT; BASAL GANGLION; CASE REPORT; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HUMAN; HUNTINGTON CHOREA; LETTER; MANIC DEPRESSIVE PSYCHOSIS; MEDLINE; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DYSKINESIA, DRUG-INDUCED; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PIRENZEPINE;

EID: 0036321441     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200208000-00020     Document Type: Letter

References (11)

1. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
2. Citalopram and desmethylcitalopram in vitro: Human cythocromes mediating transformation, and cythocromes inhibitory effects
3. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality
4. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
5. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study
6. The treatment of tardive dyskinesia and tardive dystonia
7. Treatment of central nervous system degenerative disorders
8. Roles of dopamine and its receptors in generation of choreic movements
9. The use of olanzapine for movement disorder in Huntington's disease: A first case report
10. Olanzapine and Huntington's disease